A majority of volunteers with liver damage due to hepatitis C virus (HCV) infection were cured following a six-month course of therapy that combined an experimental drug, sofosbuvir, with the licensed antiviral drug ribavirin, in a study of an all-oral drug regimen. The results showed that the regimen was highly effective in clearing the virus and well tolerated in a group of patients who historically have had unfavorable prognoses. Scientists from the National ...You have just read an article categorized health
titled NIH Trial Reveals Oral Regimen for Hepatitis C Shows Promise.
Written by:
editor - Wednesday, August 28, 2013
There are currently no comments for "NIH Trial Reveals Oral Regimen for Hepatitis C Shows Promise"
Post a Comment